Thiazolidinedione-induced skeletal fragility - Mechanisms and implications

Diabetes, Obesity and Metabolism

Volumn 11, Issue 4, 2009, Pages 275-284

  Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bone mineral density; Bone turnover; Fracture; Osteoporosis; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DARGLITAZONE; ESTROGEN; GLIBENCLAMIDE; METFORMIN; NETOGLITAZONE; PARATHYROID HORMONE[1-34]; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE; ANTIDIABETIC AGENT;

ADIPOGENESIS; BONE DEVELOPMENT; BONE FRAGILITY; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; FRACTURE; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPENIA; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; REVIEW; ANIMAL; BONE DENSITY; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BONE DENSITY; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; OSTEOPOROSIS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 61549098167     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00931.x     Document Type: Review

References (84)

1. Yki-Jarvinen H. The PROactive study: Some answers, many questions. Lancet 2005; 366: 1241-1242.
2. Watts NB, D'Alessio DA. Type 2 diabetes, thiazolidinediones: Bad to the bone? J Clin Endocrinol Metab 2006; 91: 3276-3278.
3. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
4. The Dream Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006; 368: 1096-1105.
5. Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 2005; 25: 244-252.
6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
7. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 2007; 298: 1189-1195.
8. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
9. Robert W, Stuart K, Erland E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008; 155: 712-717.
10. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
11. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.
12. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 2007; 18: 427-444.
13. Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W. Elevated hip fracture risk in type 1 diabetic patients: A population-based cohort study in Sweden. Diabetes Care 2005; 28: 2850-2855.
14. Strotmeyer ES, Cauley JA, Schwartz AV et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: The Health, Aging, and Body Composition study. Arch Intern Med 2005; 165: 1612-1617.
15. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24: 1192-1197.
16. Schwartz AV, Sellmeyer DE, Ensrud KE et al. Older women with diabetes have an increased risk of fracture: A prospective study. J Clin Endocrinol Metab 2001; 86: 32-38.
17. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48: 1292-1299.
18. Bonds DE, Larson JC, Schwartz AV et al. Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91: 3404-3410.
19. Ahmed LA, Joakimsen RM, Berntsen GK, Fonnebo V, Schirmer H. Diabetes mellitus and the risk of non-vertebral fractures: The Tromso study. Osteoporos Int 2006; 17: 495-500.
20. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 2001; 24: 1198-1203.
21. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505.
22. Whiteside GT, Boulet JM, Sellers R, Bunton TE, Walker K. Neuropathy-induced osteopenia in rats is not due to a reduction in weight borne on the affected limb. Bone 2006; 38: 387-393.
23. Cundy TF, Edmonds ME, Watkins PJ. Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet Med 1985; 2: 461-464.
24. Diascro DD, Vogel RL, Johnson TE et al. High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. J Bone Miner Res 1998; 13: 96-106.
25. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteopenic disorders. J Bone Miner Res 1998; 13: 371-382.
26. Mbalaviele G, Abu-Amer Y, Meng A et al. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 2000; 275: 14388-14393.
27. Gimble JM, Robinson CE, Wu X et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996; 50: 1087-1094.
28. Johnson TE, Vogel R, Rutledge SJ, Rodan G, Schmidt A. Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology 1999; 140: 3245-3254.
29. Jeon MJ, Kim JA, Kwon SH et al. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 2003; 278: 23270-23277.
30. Jackson SM, Demer LL. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 2000; 471: 119-124.
31. Chan BY, Gartland A, Wilson PJM et al. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007; 40: 149-159.
32. Lecka-Czernik B, Gubrij I, Moerman EJ et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999; 74: 357-371.
33. Khan E, Abu-Amer Y. Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J Lab Clin Med 2003; 142: 29-34.
34. Kawaguchi H, Akune T, Yamaguchi M et al. Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab 2005; 23: 275-279.
35. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002; 143: 2376-2384.
36. Kim SH, Yoo CI, Kim HT, Park JY, Kwon CH, Kim YK. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol Appl Pharmacol 2006; 215: 198-207.
37. Okazaki R, Toriumi M, Fukumoto S et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999; 140: 5060-5065.
38. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145: 401-406.
39. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007; 148: 2669-2680.
40. Wan Y, Chong L-W, Evans RM. PPARγ regulates osteoclastogenesis in mice. Nat Med 2007; 13: 1496-1503.
41. Lin T-H, Yang R-S, Tang C-H, Lin C-P, Fu W-M. PPARγ inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats. Bone 2007; 41: 562-574.
42. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005; 146: 1226-1235.
43. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006; 38: 74-84.
44. Soroceanu MA, Miao D, Bai X-Y, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/ osteocyte apoptosis. J Endocrinol 2004; 183: 203-216.
45. Jennermann C, Triantafillou J, Cowan D, Pennink BGA, Connolly KM, Morris DC. Effects of thiazolidinediones on bone turnover in the rat. J Bone Miner Res 1995; 10 (Suppl.1): S241.
46. Li M, Pan LC, Simmons HA et al. Surface-specific effects of a PPAR-gamma agonist, darglitazone, on bone in mice. Bone 2006; 39: 796-806.
47. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008; 19: 129-137.
48. Rosen CJ, Bouxsein ML. Mechanisms of disease: Is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006; 2: 35-43.
49. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004; 75: 329-337.
50. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 2001; 69: 46-50.
51. Akune T, Ohba S, Kamekura S et al. PPAR-gamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004; 113: 846-855.
52. Klein RF, Allard J, Avnur Z et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004; 303: 229-232.
53. Reid IR, Cornish J, Baldock PA. Nutrition-related peptides and bone homeostasis. J Bone Miner Res 2006; 21: 495-500.
54. Fain JN, Cowan GS Jr, Buffington C, Andersen RN, Pouncey L, Bahouth SW. Regulation of leptin release by troglitazone in human adipose tissue. Metabolism 2000; 49: 1485-1490.
55. Williams LB, Fawcett RL, Waechter AS et al. Leptin production in adipocytes from morbidly obese subjects: Stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J Clin Endocrinol Metab 2000; 85: 2678-2684.
56. Cornish J, Callon KE, Bava U et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002; 175: 405-415.
57. Ducy P, Amling M, Takeda S et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000; 100: 197-207.
58. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094.
59. Oshima K, Nampei A, Matsuda M et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005; 331: 520-526.
60. Williams GA, Callon KE, Watson M et al. Adiponectin Knock-out Mice have Increased Trabecular Number and Bone Volume at 14 Weeks of Age. Port Douglas: Australia New Zealand Bone and Mineral Society, 2006.
61. Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 1996; 59: 492-495.
62. Cornish J, Callon KE, King AR, Cooper GJS, Reid IR. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 1998; 38: E694-E699.
63. Dacquin R, Davey RA, Laplace C et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 2004; 164: 509-514.
64. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML et al. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007; 148: 903-911.
65. Cock T-A, Back J, Elefteriou F et al. Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Reports 2004; 5: 1007-1012.
66. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-3354.
67. Yaturu S, Bryant B, Jain SK. Thiazolidinediones treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30: 1574-1576.
68. Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab 2007; 92: 1305-1310.
69. Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Tutuncu NB, Demirag NG. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007; 92: 3523-3530.
70. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008; 93: 1696-1701.
71. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005; 20: 464-470.
72. Monami M, Cresci B, Colombini A et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: A case-control study. Diabetes Care 2008; 31: 199-203.
73. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168: 820-825.
74. US Food and Drug Administration. Available from URL: http://www.fda.gov/ medwatch/safety/2007/Avandia_GSK_Ltr.pdf. Accessed 14 April 2008.
75. US Food and Drug Administration. Available from URL: http://www.fda.gov/ medwatch/safety/2007/Actosmar0807.pdf. Accessed 15 April 2008.
76. Sanders KM, Seeman E, Ugoni AM et al. Age- and gender-specific rate of fractures in Australia: A population-based study. Osteoporos Int 1999; 10: 240-247.
77. Garraway WM, Stauffer RN, Kurland LT, O'Fallon WM. Limb fractures in a defined population. I. Frequency and distribution. Mayo Clin Proc 1979; 54: 701-707.
78. FRAX: WHO fracture risk assessment tool. AvailablH from URL: http://www.shef.ac.uk/FRAX/index.htm. Accessed 15 April 2008.
79. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292-299.
80. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-211.
81. Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol (Oxf) 1994; 40: 671-677.
82. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-2039.
83. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington: National Osteoporosis Foundation, 2003.
84. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis. Endocrine Practice 2003; 9: 544-564.